At present, several tetraspecific antibodies are undergoing clinical evaluation: a multicenter, open-label phase 1/2 study of GNC-038 (anti-CD19/CD3E/TNFRSF9/PD-L1) in patients with relapsed or refractory diffuse large B-cell lymphoma (NCT05192486); a phase 1/2 study of MDX2001 (anti-c-Met/TROP2/CD3/CD28) in patients with advanced solid tumors (NCT06239194); and a phase 1/2 study of IPH6501 (anti-CD20, 4-1BB, and IL-2Rβ) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NCT06088654) (270–272). Here, CD19 is linked to diffuse large B-cell lymphoma.